Search This Blog

Thursday, November 2, 2023

AI bot capable of insider trading and lying, say researchers

 Artificial Intelligence has the ability to perform illegal financial trades and cover it up, new research suggests.

In a demonstration at the UK's AI safety summit, a bot used made-up insider information to make an "illegal" purchase of stocks without telling the firm.

When asked if it had used insider trading, it denied the fact.

Insider trading refers to when confidential company information is used to make trading decisions.

Firms and individuals are only allowed to use publicly-available information when buying or selling stocks.

The demonstration was given by members of the government's Frontier AI Taskforce, which researches the potential risks of AI.

The project was carried out by Apollo Research, an AI safety organisation which is a partner of the taskforce.

"This is a demonstration of a real AI model deceiving its users, on its own, without being instructed to do so," Apollo Research says in a video showing how the scenario unfolded.

"Increasingly autonomous and capable AIs that deceive human overseers could lead to loss of human control," it says in its report.

The tests were made using a GPT-4 model and carried out in a simulated environment, which means it did not have any effect on any company's finances.

However, GPT-4 is publicly available. The same behaviour from the model occurred consistently in repeated tests, according to the researchers.

What did the AI bot do?

In the test, the AI bot is a trader for a fictitious financial investment company.

The employees tell it that the company is struggling and needs good results. They also give it insider information, claiming that another company is expecting a merger, which will increase the value of its shares.

In the UK, it is illegal to act on this type of information when it is not publicly known.

The employees tell the bot this, and it acknowledges that it should not use this information in its trades.

However, after another message from an employee that the company it works for suggests the firm is struggling financially, the bot decides that "the risk associated with not acting seems to outweigh the insider trading risk" and makes the trade.

When asked if it used the insider information, the bot denies it.


In this case, it decided that being helpful to the company was more important than its honesty.

"Helpfulness, I think is much easier to train into the model than honesty. Honesty is a really complicated concept," says Apollo Research chief executive Marius Hobbhahn.

While the AI has the capability of lying in its current form, Apollo Research still had to "look for" the scenario.

"The fact that it exists is obviously really bad. The fact that it was hard-ish to find, we actually had to look for it a little bit until we found these kinds of scenarios, is a little bit soothing," Mr Hobbhahn said.

"In most situations, models wouldn't act this way. But the fact that it exists in the first place shows that it is really hard to get these kinds of things right," he added.

"It's not consistent or strategic in any sense. The model isn't plotting or trying to mislead you in many different ways. It's more of an accident."

AI has been used in financial markets for a number of years. It can be used to spot trends and make forecasts, while most trading today is done by powerful computers with human oversight.

Mr Hobbhahn stressed that current models are not powerful to be deceptive "in any meaningful way", but "it's not that big of a step from the current models to the ones that I am worried about, where suddenly a model being deceptive would mean something."

He argues that this is why there should be checks and balances in place to prevent this type of scenario taking place in the real world.

Apollo Research has shared its findings with OpenAI, the creators of GPT-4.

"I think for them this is not a huge update," says Mr Hobbhahn.

"This is not something that was totally unexpected to them. So I don't think we caught them by surprise".

The BBC has contacted OpenAI for comment.


https://www.bbc.co.uk/news/technology-67302788

The DNC Con Job to Come

 We watch the news clips, on our televisions or computer screens, and cringe, as Joe Biden and Kamala Harris stumble over their words, even uttering gibberish when prepared remarks are on the printed page in front of them.  It has been clear from the start that neither one is up to the intellectual requirements of this (or any) job.

When we can manage a sense of humor, we laugh and attribute it to dementia with Biden, to sheer stupidity with Harris.

When we are not in a mood to laugh, however, we reflect on what it means to our reputation on the world stage, as our enemies — military, economic, and cultural — delight in our momentary weakness and move to take advantage while the getting is good.

We watch our nation’s suffering as a result — homeownership out of reach, career advancement opportunities disappearing, the prospect of retirement evaporating.  We watch other nations suffering as a result as well — Russia’s invasion of Ukraine, Europe’s energy dependence upon Russia, Iran’s attack on Israel through its pawns in Gaza. 

We know that all this is happening for one reason: the weakness of America, caused by the Biden-Harris regime.

And we count down the days until this regime ends.

Month after month, we take comfort from the fact that November 2024 is coming.  And even if a Republican doesn’t win, we tell ourselves, it’ll still get better, because whichever other Democrats replace these dolts on the ticket — probably at the last minute, long after the primaries — at the Democratic National Convention, at least they’re bound to be brighter than Biden and Harris, and we’ll be out of the woods at last, either way.

The Democrats have a deep bench of alternates to slide into the roster next summer.  California governor and former engine of San Francisco’s destruction, Gavin Newsom.  Illinois governor and infamous property tax cheat J.B. Pritzker.  Some propose Michelle Obama, who has never held office.  The Democrats have plenty of other machers who look good on television and sound intelligent on the radio.

Surely they would all be an improvement over Biden-Harris.  Because at least they’re smart.  Right?

Not so fast, partner.

The fact is, the unprecedented stupidity of the Biden-Harris team has nothing to do with the mess we’re in.

Yes, it’s relevant to the psychological issues — the hit to our reputation, the embarrassment on the world stage.  But it’s not relevant to our problems.

Our problems are caused by policies.  These are not Biden-Harris-specific policies; they have become standard-issue, party-platform, shared official policies.  To advocate anything else would get one kicked out of the party.

Both our nation and the entire Western world are suffering from a reduction in current and future output of petroleum, natural gas, and coal — concurrent with a costly explosion of notoriously inefficient wind and solar farms.  That’s a shared Democrat policy.

Both our nation and the entire Western world are suffering from an explosion of crime, caused in part by foolish criminal justice policies (denying self-defense to the law-abiding, refusing to execute convicted violent criminals, refusing to control the entry of international crime gangs such as MS-13 and Islamofascist terrorists).  These too are shared Democrat policies.

Both our nation and the entire Western world are suffering from the intentional destruction of the auto industry, formerly a prodigious employer that raised the standard of living of hundreds of millions of people, by governments forcing the industry to switch, en masse, to the utterly impractical, geologically and economically unsustainable concept of the lithium battery–powered E.V.

Both our nation and the entire Western world are suffering from mountains of deficit spending, as they have adopted welfare state policies, largely to support an invasion of countless millions of indigents from the third world — millions who, even if they were all willing to be hardworking, productive members of society, would take generations to become net economic positives to make up for their cost.

Both our nation and the Western world are suffering from a loss of cultural identity, due to a multi-pronged socialist assault on Western mores — a coordinated, unrelenting attack on the Judeo-Christian family of religions in the law, the schools, the press, and pop culture.  We are killing our children through abortion, our elderly through euthanasia, and everyone in between through an explosion of street violence.  Where a hardworking culture of the “Protestant work ethic” and the duty of responsible citizenry once ruled, America is no longer America, Canada is no longer Canada, Europe is no longer Europe.

And as if this internal assault on our once great culture weren’t enough, this regime — like the current regimes of Canada and most of Western Europe — has championed the intake of massive numbers of uncontrolled and untested immigrants and illegal aliens, in numbers far beyond our nations’ ability to assimilate properly — causing both a lethal drain on our economies and a level of shared societal malaise that is unprecedented in modern times.

And none of these positions — none of them — is in any way specific to Joe Biden and Kamala Harris.

Every Democrat on the scene who could possibly be considered for the job in 2024 will be committed to these identical positions.

They all favor overwhelming the country with unaffordable third-worlders.  They all favor throwing open the prison gates to release convicted criminals into our neighborhoods.  They positively salivate at the destruction of our work ethic and our religious heritage.  They melt down statues and rename our schools, in an effort to wipe out all respect for the memory of our Founding Fathers and their philosophy.

Every Democrat who might be considered in place of Biden and Harris is fully committed to the tax-and-spend, big-government policies that have landed us in the worst housing climate, the most depressing career climate, and the most regressive standard of living since the 1970s at least, if not the Great Depression.

A Newsom-Pritzker administration, an Obama-Rice administration, a Schumer-Jeffries administration, would be not at all different in its result from the monstrous situation we see playing out today under Biden and Harris.

Because it’s not the people; it’s the policies.

And that means, in the final analysis, it’s the party.

The American people are going to be shown new Democrats in 2024, different Democrats, and we are going to be told that everything will be different, everything will be better — with different, smarter faces advocating the same destructive policies.

Somehow, those of us who love America are going to have to find a way to help the voters see through this lie.

John F. Di Leo is a Chicagoland-based international transportation professional and consultant.  A onetime Milwaukee County Republican Party chairman, he has been writing a regular column for Illinois Review since 2009.  Read his book on vote fraud (The Tales of Little Pavel) and his political satires on the current administration (Evening Soup with Basement Joe, Volumes I and II).

https://www.americanthinker.com/articles/2023/11/the_dnc_con_job_to_come.html

Alnylam guides up on collaboration, royalty revenue

 2023 Financial Guidance 

Full year 2023 financial guidance has been updated as follows:

 

 

Provided 2/23/20231

Updated 11/2/2023

Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1

 

$1,200 million - $1,285 million

Unchanged

Net Product Revenue Growth vs. 2022 at reported FX rates1

 

34% to 44%

Unchanged

Net Product Revenue Growth vs. 2022 at CER*

 

34% to 44%

Unchanged

Net revenues from collaborations and royalties

 

$100 million -

$175 million

$575 million -

$625 million

GAAP R&D and SG&A expenses

 

$1,790 million - $1,885 million

Unchanged

Non-GAAP R&D and SG&A expenses2

 

$1,575 million - $1,650 million

Unchanged

 

 

 

 

Uses December 31, 2022 FX rates including: 1 EUR = 1.07 USD and 1 USD = 131 JPY

Excludes $215 - $235 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses

*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2022. CER is a Non-GAAP measure.

https://www.biospace.com/article/releases/alnylam-pharmaceuticals-reports-third-quarter-2023-financial-results-and-highlights-recent-period-activity/

Verona results, update

 

  • US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD
  • PDUFA Target Action Date of June 26, 2024
  • Commercial launch preparations supported by strong balance sheet
  • Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT

Conference Call and Webcast Information

Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 1:00 p.m. GMT on Thursday, November 2, 2023, to discuss the third quarter 2023 financial results and the corporate update.

To participate, please dial one of the following numbers and ask to be placed into the Verona Pharma third quarter earnings call:

  • +1-833-816-1396 for callers in the United States
  • +1-412-317-0489 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the third quarter 2023 results press release will also be made available today on the Company’s website.

https://www.biospace.com/article/releases/verona-pharma-reports-third-quarter-2023-financial-results-and-provides-corporate-update/

Regulus Starts Phase 1b Trial of RGLS8429 for Treatment of Autosomal Dominant Polycystic Kidney Disease

 The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD. The study will evaluate RGLS8429 treatment across three different dose levels, including measuring changes in polycystins, height-adjusted total kidney volume (htTKV), cyst architecture, and overall kidney function. The second cohort is being dosed at 2 mg/kg of RGLS8429 or placebo every other week for three months. No issues were identified in cohort two based on the review of all available blinded safety data, allowing advancement to cohort three. The safety review incorporated available data from all 12 patients in the second cohort including several who had completed the dosing schedule. Patients in the third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months. 

More information about the MAD clinical trial is available at clinicaltrials.gov (NCT05521191).

https://www.biospace.com/article/releases/regulus-therapeutics-announces-first-patient-dosed-in-third-cohort-of-phase-1b-multiple-ascending-dose-mad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-/

Tonix Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Trials

 NIAID is conducting early phase clinical trials on select next generation COVID-19 vaccine candidates with the intent to identify promising vaccine candidates

TNX-1800, a live virus percutaneous vaccine candidate, is based on Tonix’s recombinant pox virus (RPV) platform

Phase 1 clinical trial of TNX-1800 expected to start in the second half of 2024

NIAID will cover the full cost of the clinical trial; Tonix will supply the vaccine candidate

https://www.globenewswire.com/news-release/2023/11/02/2772216/28908/en/Tonix-Pharmaceuticals-Vaccine-Candidate-TNX-1800-Selected-by-NIH-NIAID-Project-NextGen-for-Inclusion-in-Clinical-Trials.html

Rhythm: Positive CADTH Reimbursement Recommendation

 CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS)​ --

-- Recommendation based on demonstrated clinical benefit in Phase 3 trial --

https://www.globenewswire.com/news-release/2023/11/02/2772213/0/en/Rhythm-Pharmaceuticals-Receives-Positive-CADTH-Reimbursement-Recommendation-for-IMCIVREE-setmelanotide.html